{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:27:42Z","timestamp":1787772462039,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"\n OBJECTIVES:<\/jats:title>\n Chronic constipation (CC), a common functional gastrointestinal disorder, has laxatives as its mainstay of treatment. Refractoriness to laxatives calls for better treatment options. Prucalopride is a novel, well-tolerated enterokinetic with high 5-hydroxytryptamine 4 receptor selectivity. This study was undertaken with the intention to establish the efficacy and safety of prucalopride with placebo in adults with refractory CC.<\/jats:p>\n <\/jats:sec>\n \n MATERIALS AND METHODS:<\/jats:title>\n \n Patients were screened and 180 patients fulfilling the inclusion criteria were simply randomized into 2 groups either to receive prucalopride 2 mg (\n n<\/jats:italic>\n = 90) or placebo (\n n<\/jats:italic>\n = 90) once daily for a duration of 12 weeks. The efficacy endpoints (primary) were intended to measure the proportion of patients with three or more spontaneous complete bowel movements (SCBMs) per week over 12 weeks. Secondary endpoints were assessed via the validated questionnaires. Adverse events, electrocardiogram, and other laboratory parameters were monitored at different time intervals.\n <\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n \n Efficacy and safety were analyzed in 180 patients simply randomized (1:1) into group A (prucalopride arm,\n n<\/jats:italic>\n = 90) and group B (placebo arm,\n n<\/jats:italic>\n = 90). Patients having three or more SCBMs per week in the prucalopride arm (2 mg) were 41% as against to 12% in the placebo arm (\n P<\/jats:italic>\n < 0.001). A significant increase (\n P<\/jats:italic>\n < 0.001) in the number of spontaneous bowel movements per week plus an increase of average bowel movement by 1 point per week was seen in the prucalopride arm. Secondary efficacy endpoints which included patients' treatment satisfaction, improvement in the perception of constipation symptoms using the patient assessment of constipation -symptoms and stool consistency score changes were more pronounced in the prucalopride arm than the placebo. The most common adverse events reported from both the groups were headache, nausea, bloating, and diarrhea. No significant cardiovascular changes or laboratory abnormality was detected throughout the study period.\n <\/jats:p>\n <\/jats:sec>\n \n CONCLUSION:<\/jats:title>\n Prucalopride is effective in laxative refractory CC cases with a good safety profile.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijp.ijp_530_22","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T16:02:39Z","timestamp":1716480159000},"page":"6-13","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety analysis of prucalopride in refractory chronic constipation cases in a tertiary care hospital in Eastern India"],"prefix":"10.4103","volume":"55","author":[{"given":"Suhasini","family":"Dehury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourya","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haribhakti Seba","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Goutam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetna","family":"Kaushik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240903","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1572-0241.2004.04114.x","article-title":"Epidemiology of constipation in North America: A systematic review","volume":"99","author":"Higgins","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R2-2-20240903","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.gastro.2012.10.028","article-title":"American gastroenterological association technical review on constipation","volume":"144","author":"Bharucha","year":"2013","journal-title":"Gastroenterology"},{"key":"R3-2-20240903","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/ajg.2011.164","article-title":"Prevalence of, and risk factors for, chronic idiopathic constipation in the community: Systematic review and meta-analysis","volume":"106","author":"Suares","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R4-2-20240903","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/SGA.0000000000000074","article-title":"Prevalence of constipation among the general population: A community-based survey from India","volume":"37","author":"Rajput","year":"2014","journal-title":"Gastroenterol Nurs"},{"key":"R5-2-20240903","first-page":"919","article-title":"Epidemiology and management of chronic constipation in elderly patients","volume":"10","author":"Vazquez Roque","year":"2015","journal-title":"Clin Interv Aging"},{"key":"R6-2-20240903","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1586\/17474124.2016.1129897","article-title":"Prucalopride succinate for the treatment of constipation: An update","volume":"10","author":"Bassotti","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R7-2-20240903","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2009.04169.x","article-title":"Survey of laxative use by adults with self-defined constipation in South America and Asia: A comparison of six countries","volume":"31","author":"Wald","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-2-20240903","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1023\/A:1020131126397","article-title":"Lack of objective evidence of efficacy of laxatives in chronic constipation","volume":"47","author":"Jones","year":"2002","journal-title":"Dig Dis Sci"},{"key":"R9-2-20240903","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"R10-2-20240903","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/ajg.2010.70","article-title":"Anorectal disorders","volume":"105","author":"Bharucha","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R11-2-20240903","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2982.2001.00280.x","article-title":"Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs","volume":"13","author":"Briejer","year":"2001","journal-title":"Neurogastroenterol Motil"},{"key":"R12-2-20240903","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa0800670","article-title":"A placebo-controlled trial of prucalopride for severe chronic constipation","volume":"358","author":"Camilleri","year":"2008","journal-title":"N Engl J Med"},{"key":"R13-2-20240903","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/apt.12571","article-title":"Systematic review with meta-analysis: Highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation","volume":"39","author":"Shin","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R14-2-20240903","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1365-2036.2010.04455.x","article-title":"Clinical trial: The efficacy of open-label prucalopride treatment in patients with chronic constipation \u2013 Follow-up of patients from the pivotal studies","volume":"32","author":"Camilleri","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R15-2-20240903","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1046\/j.1365-2036.2002.01272.x","article-title":"Prucalopride, a systemic enterokinetic, for the treatment of constipation","volume":"16","author":"Emmanuel","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-2-20240903","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000070202","article-title":"Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial","volume":"67","author":"Coremans","year":"2003","journal-title":"Digestion"},{"key":"R17-2-20240903","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/003655299750025327","article-title":"Psychometric validation of a constipation symptom assessment questionnaire","volume":"34","author":"Frank","year":"1999","journal-title":"Scand J Gastroenterol"},{"key":"R18-2-20240903","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"R19-2-20240903","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/00365520510012208","article-title":"Development and validation of the patient assessment of constipation quality of life questionnaire","volume":"40","author":"Marquis","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"R20-2-20240903","first-page":"C01","article-title":"Evaluation of the symptom of constipation in Indian patients","volume":"10","author":"Ray","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"R21-2-20240903","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s12664-014-0505-8","article-title":"Clinical and investigative assessment of constipation: A study from a referral center in Western India","volume":"33","author":"Shah","year":"2014","journal-title":"Indian J Gastroenterol"},{"key":"R22-2-20240903","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/gut.2008.162404","article-title":"Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives","volume":"58","author":"Tack","year":"2009","journal-title":"Gut"},{"key":"R23-2-20240903","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2036.2008.03884.x","article-title":"Clinical trial: The efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation \u2013 A 12-week, randomized, double-blind, placebo-controlled study","volume":"29","author":"Quigley","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R24-2-20240903","doi-asserted-by":"crossref","first-page":"998","DOI":"10.18203\/2319-2003.ijbcp20181649","article-title":"Efficacy and safety of prucalopride in the treatment of chronic constipation","volume":"7","author":"Kanaki","year":"2018","journal-title":"International Journal of Basic and Clinical Pharmacology"},{"key":"R25-2-20240903","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/2050640614558476","article-title":"Chronic constipation and co-morbidities: A prospective population-based nested case-control study","volume":"4","author":"Choung","year":"2016","journal-title":"United European Gastroenterol J"},{"key":"R26-2-20240903","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5056\/jnm17112","article-title":"Lower and upper gastrointestinal symptoms differ between individuals with irritable bowel syndrome with constipation or chronic idiopathic constipation","volume":"24","author":"Shah","year":"2018","journal-title":"J Neurogastroenterol Motil"},{"key":"R27-2-20240903","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3748\/wjg.v13.i5.732","article-title":"A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation","volume":"13","author":"Lin","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R28-2-20240903","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s12664-018-0894-1","article-title":"Indian consensus on chronic constipation in adults: A joint position statement of the Indian motility and functional diseases association and the Indian society of gastroenterology","volume":"37","author":"Ghoshal","year":"2018","journal-title":"Indian J Gastroenterol"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_530_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:48:15Z","timestamp":1787770095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_530_22"}},"subtitle":["A randomized, single-blind, placebo-controlled study"],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_530_22","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}